Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Monika Fischer, Dina Kao, Colleen Kelly, Aishwarya Kuchipudi, Syed Mohammed Jafri, Mark Blumenkehl, Douglas Rex, Mark Mellow, Nirmal Kaur, Harry Sokol, Gwen Cook, Matthew J. Hamilton, Emmalee Phelps, Brian Sipe, Huiping Xu, Jessica R. Allegretti

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Abstract

Background: New treatments are needed as Clostridium difficile infection (CDI) is becoming increasingly formidable. Fecal microbiota transplantation (FMT) has a 90% success rate in the treatment of recurrent CDI. However, evidence regarding its safety, efficacy, and effect on disease activity in patients with inflammatory bowel disease (IBD) is lacking. Methods: This cohort study used data from 8 national and international academic centers. Patients with established IBD who underwent FMT for recurrent CDI were followed for a minimum of 3 months. The primary outcome was CDI recurrence at 3 months after FMT. The secondary outcomes were (1) IBD activity and severity at 3 months based on the judgment of the treating physician, endoscopic findings, and clinical disease activity scores; and (2) safety. Results: Sixty-seven patients were included in the analysis. Thirty-five (52%) had Crohn's disease, 31 (46%) ulcerative colitis, and one indeterminate colitis with 43 (64%) patients on an immunosuppressive agent at the time of FMT. The initial FMT was successful in 53 (79%) patients. After the FMT, IBD disease activity was reported as improved in 25 (37%), no change in 20 (30%), and worse in 9 (13%) patients. Serious adverse events included colectomy (1.4%), hospitalization for CDI (2.9%), hospitalization for IBD flare (2.9%), small bowel obstruction (1.4%), CMV colitis (1.4%), and pancreatitis (1.4%). Discussion: The overall CDI cure rates were high, with a large percentage of patients experiencing clinical improvement of their IBD after FMT. A minority of patients developed an IBD flare. No severe adverse events directly attributable to FMT were found in this largest reported series of recurrent or refractory CDI patients with concurrent IBD.

Original languageEnglish (US)
Pages (from-to)2402-2409
Number of pages8
JournalInflammatory bowel diseases
Volume22
Issue number10
DOIs
StatePublished - Aug 26 2016

Keywords

  • Clostridium difficile
  • Crohn's disease
  • FMT
  • IBD
  • fecal microbiota transplantation
  • inflammatory bowel disease
  • pseudomembranous colitis
  • ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Fingerprint Dive into the research topics of 'Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this